Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

Journal of the American College of Cardiology

Volumn 43, Issue 4, 2004, Pages 642-648

  Horwich, Tamara B ^a   MacLellan, W Robb ^a   Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin converting enzyme; Confidence interval; Coronary artery disease; Ejection fraction; Endothelial nitric oxide synthase; Hazard ratio; Heart failure; Low density lipoprotein; Nitric oxide

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; SPIRONOLACTONE;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG SAFETY; DRUG THERAPY; FEMALE; FOLLOW UP; GENDER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SURVIVAL; SURVIVAL RATE; TIME; UNIVERSITY HOSPITAL;

EID: 1242295184     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.07.049     Document Type: Article

References (35)

1. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
3. The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo controlled trial . Lancet. 360:2002;7-22.
4. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
5. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 3:1997;249-254.
6. Aronow W.S., Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid lowering drug. Am J Cardiol. 90:2002;147-149.
7. Lefer D.J. Statins as potent anti-inflammatory drugs. Circulation. 106:2002;2041-2042.
8. von Haehling S., Anker S.D., Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev. 8:2003;99-106.
9. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 353:1999;983-984.
10. Hayashidani S., Tsutsui H., Shiomi T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 105:2002;868-873.
11. Dechend R., Fiebeler A., Park J.K., et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation. 104:2001;576-581.
12. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107:2493-8.
13. Maggioni A.P. Debate should statin be used in patients with heart failure? Curr Control Trials Cardiovasc Med. 2:2001;226-227.
14. Krum H., McMurray J.J. Statins and chronic heart failure do we need a large-scale outcome trial? J Am Coll Cardiol. 39:2002;1567-1573.
15. Horwich T.B., Hamilton M.A., MacLellan W.R., Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 8:2002;216-224.
16. Rauchhaus M., Koloczek V., Hans-Dieter V., et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol. 76:2000;125-133.
17. Ashton E., Liew D., Krum H. Should patients with chronic heart failure be treated with 'statins'? Heart Fail Monit. 3:2003;82-86.
18. Sueta C.A., Massing M.W., Chowdhury M., Biggs D.P., Simpson R.J. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. J Card Fail. 9:2003;36-41.
19. Uretsky B.F., Thygesen K., Armstrong P.W. Acute coronary findings at autopsy in heart failure patients with sudden death results from the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial . Circulation. 102:2000;611-616.
20. Fonarow G.C., Stevenson L.W., Walden J.A. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 30:1997;725-731.
21. Aaronson K.D., Mancini D.M. Mortality remains high for outpatient transplant candidates with prolonged (>6 months) waiting list time. J Am Coll Cardiol. 33:1999;1189-1195.
22. Remme W.J. Overview of the relationship between ischemia and congestive heart failure. Clin Cardiol. 23:(Suppl IV):2000;IV4-8.
23. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins. JAMA. 279:1998;1643-1650.
24. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
25. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:2000;1004-1010.
26. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., Ertl G. Improvement of left ventricular remodeling and function by hyroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure. Circulation. 104:2001;982-985.
27. Indolfi C., Di Lorenzo E., Perrino C., et al. Hydroxymethylgluatryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation. 106:2002;2118-2124.
28. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure an analysis of the cytokine database from the VESnarinone Trial (VEST) . Circulation. 103:2001;2055-2059.
29. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 102:2000;3060-3067.
30. Feldman A.M., Combes A., Wagner D., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 35:2000;537-544.
31. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin and plasma concentration of C-reactive protein. Circulation. 100:1999;230-235.
32. Katz S.D., Khan T., Zeballos G. Decreased activity of L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation. 99:1999;2113-2117.
33. Jones S.P., Greer J.J.M., van Haperen R., Duncker D.J., de Crom R., Lefer D.J. Endothelial nitric oxide synthase overexpression in mice attenuates congestive heart failure in mice. Proc Natl Acad Sci USA. 100:2003;4891-4896.
34. Cohn J.N., Johnson G.R., Shabetai R., et al. Mechanistic data from the VA Cooperative studies ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure . Circulation. 86:(Suppl VI):1993;VI-5-16.
35. Pliquett RU, Cornish KG, Zudker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003;95:700-4.